ROCKVILLE, Md., Aug. 29,
2023 /PRNewswire/ -- Shuttle Pharmaceuticals
Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage
specialty pharmaceutical company focused on improving the outcomes
of cancer patients treated with radiation therapy (RT), today
announced the publication of a manuscript reporting on the ability
of Shuttle's lead Histone deacetylase 6 (HDAC6) inhibitor drug
candidate (SP-2-225) to stimulate the innate immune system
following radiation therapy. The manuscript, titled "Radiation
therapy-induced immune response enhanced by selective HDAC6
Inhibition," was reported by first author Dr. Satish Noonepalle,
Assistant Professor at Georgetown
University and the Lombardi Comprehensive Cancer Center, and
published in Molecular Cancer Therapeutics, a scientific journal
affiliated with the American Association for Cancer Research
(AACR), the premier international cancer research society.
"The report highlights to the scientific and financial community
how our novel selective inhibitor (SP-2-225) is able to target the
HDAC6 function in tumors to inhibit tumor growth and enhance the
M1/M2 ratio of infiltrating macrophages within tumors as a
combination therapy with RT," commented Anatoly Dritschilo, M.D., CEO of Shuttle
Pharmaceuticals and a co-author of the report. "These observations
support a strategy to advance the use of selective HDAC6 inhibitors
to improve antitumor immune responses and prevent tumor relapse
post-radiation therapy."
RT is a curative cancer treatment modality that imparts damage
to cellular DNA, induces immunogenic cell death, and activates
antitumor immunity. Despite the RT-induced direct antitumor effect
seen within the treated volume, accumulating evidence indicates
activation of innate antitumor immunity. Acute proinflammatory
responses mediated by anticancer M1 macrophages are observed in the
immediate aftermath following RT. However, after a few days, these
M1 macrophages are converted to anti-inflammatory and pro-cancer M2
phenotype, leading to cancer resistance and underlying potential
tumor relapse.
The study was supported by NIH grant R01CA249248, and
Cancer Research Institute Grant #228514 to Dr. Alejandro
Villagra, and HDAC6 inhibitor SP-2-225 was provided at no
charge by Shuttle Pharmaceuticals, Inc. under a material transfer
agreement.
A copy of the publication is available at:
https://pubmed.ncbi.nlm.nih.gov/37586844/
Molecular Cancer Therapeutics publishes translational research
studies focused on the discovery and preclinical development of
therapeutic agents for oncology. To reflect the evolving
field of therapeutics, the journal's interest extends to all
selective drugs including small molecule inhibitors, antibody-drug
conjugates, antibody cytokine fusions, bispecific antibodies, cell
therapies, gene therapies, radio-immunotherapeutics, vaccines,
viral therapies, and other experimental approaches in oncology.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown
University Medical Center, Shuttle Pharmaceuticals is a
discovery and development stage specialty pharmaceutical company
focused on improving the outcomes for cancer patients treated with
radiation therapy (RT). Our mission is to improve the lives of
cancer patients by developing therapies that are designed to
maximize the effectiveness of RT while limiting the side effects of
radiation in cancer treatment. Although RT is a proven modality for
treating cancers, by developing radiation sensitizers, we aim to
increase cancer cure rates, prolong patient survival and improve
quality of life when used as a primary treatment or in combination
with surgery, chemotherapy and immunotherapy. For more information,
please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements." These statements include, but are not
limited to, statements concerning the development of our company.
The words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "will," "would" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including factors discussed in the "Risk
Factors" section of Shuttle Pharma's Annual Report on Form 10-K for
the year ended December 31, 2022,
filed with the SEC on March 15, 2023,
its Quarterly Reports on Form 10-Q for the periods ended
March 31, 2023 and June 30, 2023, filed with the SEC on May 25, 2023 and August
14, 2023, respectively, as well as other SEC filings. Any
forward-looking statements contained in this press release speak
only as of the date hereof and, except as required by federal
securities laws, Shuttle Pharmaceuticals specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/shuttle-pharmas-selective-hdac6-inhibitor-shown-to-stimulate-innate-immune-response-in-pre-clinical-studies-as-reported-in-molecular-cancer-therapeutics-301911994.html
SOURCE Shuttle Pharmaceuticals Holdings, Inc.